Nizar Chahin, MD
Neurology · Portland, ORNPI 1225015761
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,358 of the $56,540 with a category attached, or 76.7%. 8 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 29.5% of the total. Reporting peaked in 2022 at $17,557 and has fallen 62.3% since, to $6,623 in 2025. Among neurology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $869.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$17K
- Argenx US, Inc.$15K
- Amicus Therapeutics, Inc.$11K
- Sanofi$11K
- Janssen Scientific Affairs, LLC$2K
- AstraZeneca$105
- plus $41 from 2 others
Across 179 payments — averaging $7479.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$970K
- Argenx US, Inc.$193K
- Sanofi$76K
- Vertex$34K
- Janssen Research & Development, LLC$19K
- Amicus Therapeutics, Inc.$17K
- plus $30K from 4 others
What the payments were for
- Consulting fees$43,35877%
- Travel & lodging$10,42818%
- Food & beverage$2,7145%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 20 | $16,676 |
| Argenx US, Inc. | 20 | $15,136 |
| Amicus Therapeutics, Inc. | 9 | $11,491 |
| Sanofi | 11 | $10,903 |
| Janssen Scientific Affairs, LLC | 1 | $2,188 |
| AstraZeneca | 1 | $105 |
| UCB, Inc. | 2 | $30 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POMBILITI$11,023
- OPFOLDA$11,023
- LUMIZYME$10,623
- VYVGART$8,156
- Exondys 51$5,082
- VYVGART HYTRULO$121
- ULTOMIRIS$105
How this compares
$56,540 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 37 | $2,262,025 |
| EvrysdiRisdiplam | 31 | $827,490 |
| Radicava OrsEdaravone | 50 | $717,880 |
| WainuaEplontersen Sodium | 17 | $691,393 |
| NexviazymeAvalglucosidase Alfa-Ngpt | 20 | $595,607 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $354,093 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $275,643 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $217,189 |
| HyqviaIgg/Hyaluronidase,recombinant | 31 | $160,551 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $140,269 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $101,528 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $35,001 |
| Mycophenolate Mofetil | 148 | $17,541 |
| Riluzole | 75 | $13,702 |
| Pyridostigmine Bromide | 96 | $6,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaWainua | $105 | $691,39317 claims |
| SanofiNexviazyme | $10,903 | $595,60720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 neurology providers in Oregon.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
- Severine KakoPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.